KRAS and non-small cell lung carcinoma: The adaptive PERK/p-eIF2α branch of the UPR has been identified as a critical component of tumorigenesis, particularly in KRAS (Kirsten rat sarcoma viral oncogene homolog)-driven tumors representing an NSCLC subtype often resistant to treatment [23].